H1 secures $40M from CVS, proving SaaS startups can still attract investment

H1 raised $40 million in a new round led by CVS Health Ventures, despite not actively seeking capital. The nine-year-old healthcare data platform says it turned cash flow and EBITDA profitable last year and is forecasting over 40% growth this year. The article frames H1 as a data-centric SaaS business that could benefit from AI adoption rather than be displaced by it.

Analysis

The market is drawing the wrong conclusion from the AI washout: not all software is equally exposed, and the real bifurcation is between commoditizable workflow layers and proprietary data networks. Businesses that sit on scarce, continuously refreshed human or industrial datasets should see a valuation re-rate versus generic SaaS because AI is more likely to increase demand for their data than displace it. That creates a second-order winner set in private markets: data aggregators, compliance-heavy information networks, and vertical intelligence providers with switching costs embedded in downstream workflows.

The near-term implication is less about H1 specifically and more about the funding bar for legacy SaaS. If AI-native tools can replicate workflow, then capital will keep migrating away from seat-based software into data moats and distribution moats; that should pressure public comps with low differentiation and weak net retention while supporting names that monetize proprietary information. In healthcare, the likely beneficiaries are data infrastructure and provider-network businesses, while losers are point solutions whose value proposition is mostly interface and automation.

The contrarian point is that "data moat" is not a permanent moat unless the data is exclusive, high-frequency, and legally usable. Over the next 12-24 months, model makers may become customers of data vendors, but they will also push hard to internalize or synthesize those datasets once ROI is proven. That means the multiple expansion is real but should be capped unless management can show recurring expansion revenue, accelerating gross margins, and evidence that AI usage increases rather than substitutes demand.

Key Decisions for Investors

• Long a basket of high-quality data-network healthcare and vertical information names vs. short low-differentiation SaaS with AI-exposed workflows; structure as a 6-12 month pair trade and target 15-25% relative performance if the market keeps repricing AI risk.
• Avoid or underweight mature horizontal SaaS that sells process automation without proprietary data; these names likely face multiple compression over the next 2-4 quarters as AI-feature parity becomes obvious.
• For public healthcare data and analytics beneficiaries, use pullbacks to add exposure only if management can evidence >20% growth with improving EBITDA margin; otherwise the story is narrative-driven and vulnerable to a 1-2 quarter reset.
• Consider small tactical long exposure to AI infrastructure or data-demand beneficiaries rather than generic AI application plays; the best risk/reward is where AI adoption increases consumption of scarce datasets, not where it automates the core product.
• If there is a public comp with a similar economics profile to H1, buy on any post-earnings weakness and hedge with a short in an AI-vulnerable SaaS index or basket; the asymmetric setup is strongest when the market is overpricing replacement risk.